ReviewResearch (Washington, D.C.)2026
Microfluidic Chip Platforms for Red Blood Cell Storage Lesion Quality Control and Precision Transfusion.
Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physicochemically-guided immunomodulatory biomaterials for regulating immune responses in rheumatoid arthritis.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red blood cell (RBC) transfusion is a core clinical intervention. However, hypothermic storage induces progressive biochemical, structural, and functional impairments collectively termed the RBC storage lesion (RSL), which compromises post-transfusion efficacy and safety. Conventional RSL detection relies on bulk population-averaged indicators with low physiological relevance and no single-cell resolution, failing to capture cellular heterogeneity and microcirculatory dysfunction. Lab-on-a-chip (LOC) platforms are established with microfluidic technology, and organ-on-a-chip represents a biomimetic and advanced extension of such systems. Together, they enable biomimetic reconstruction of the in vivo microcirculatory microenvironment, high-throughput single-cell analysis, and quantitative assessment of RBC mechanical phenotypes under physiological shear conditions. Distinct from fragmented prior reviews that separate microfluidic engineering from transfusion clinical demands, this work systematically outlines the molecular mechanisms and clinical impacts of RSL alongside unresolved detection bottlenecks, and builds an integrated LOC-endothelium-on-a-chip technical framework covering structural design, biocompatible material screening, and standardized fabrication workflows. It further summarizes microfluidic core applications including single-cell deformability quantification, stiffness evaluation, hemolysis susceptibility testing, microvascular occlusion simulation, and RBC-endothelial interaction analysis. Uniquely, it constructs a tiered translational roadmap integrating microfluidics with multi-omics, artificial intelligence, vascularized multi-organ chips, and function-centered pre-transfusion surveillance, and proposes microfluidic strategies to optimize RBC storage regimens. In summary, microfluidic technology overcomes the limitations of conventional assays for RSL quality control, provides an emerging technical platform for RSL mechanistic research, pretransfusion quality evaluation, and donor-specific precise matching, and promotes the transformation of transfusion medicine from time-based empirical management to function-oriented precision practice.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.